Link to the Facebook group: The Root to Rx Lab - where discussion, collaboration, and questions can be worked through as a team.

Debby had closed her laptop the night Vera posted. The OPEN card was still on her desk from her friend, Cora. She had read the first line 3 times. Own your intention. Are you here to help, or here to win?

She had spent the evening after Vera’s post thinking about how many times she had been the wrong kind of helpful. So she did not post. She was done trying to win. She wanted to know.

Then she did something she had never done with a thing she wanted to disbelieve. She went looking for the lie on purpose.

She wrote the question down before she started. The first one from the toolkit. What evidence would actually change my mind?

Her answer was specific. If the 72-day approval was bought, there would be a bought or bribed yes somewhere in the record. A reviewer with a stake. A vote that was never really in doubt. A board that worked for the company it was supposed to judge. Find that, and the whole thing falls.

Then she went looking for it.

She ran the ninth question through everything she could pull up. What do independent experts with no stake in the outcome say?

The advisory committee that reviewed Gleevec had no financial relationship with Novartis. The vote was unanimous. The FDA had its own statisticians, and they ran their own analysis of the submitted data, separate from the company’s. The data safety monitoring board that recommended stopping the trial early did not work for the people who stood to profit.

Every place she expected to find the stake, she found a wall built to keep the stake out.

It was not any single fact. It was the accumulation of it.

She pushed harder. Independent on paper is easy. She wanted a case where the money won anyway. Show me where a company paid the fee and bought the yes.

Rooty the Researcher had been quiet. Rooty posted once.

Rooty: 2016. A drug called olaratumab. A small trial, 66 patients, showed people living about 12 months longer in a cancer where you measure gains in weeks. The FDA approved it. The company priced it near $19,000 a month.

Rooty: Then the FDA made them run the bigger trial they had promised. More than 500 patients. The drug did nothing. The company pulled it in 2019. They paid the fee. They did not get to keep the yes.

Debby sat with that. It was the evidence that would have changed her mind, and it pointed the other way. The fee buys the review. It does not buy the verdict. When the data said no, the answer was no, and a drug somebody was already selling came off the shelf.

She ran the fourth question last. Who funded this, and do they have a stake in the answer? Novartis did. That is in the record, in the open, which is the whole point. The stake is named so everyone can watch for it.

Then she did the part she would not have done a year ago. Debby the Denier asked the same question of the people who had told her it was all bought. Who were they, and what did they gain if she believed them? Some of them were selling the thing you take instead. Her distrust was their product.

Same standard, both directions. She had finally turned the question on her own side too. Debby was now, Debby the Skeptic, in training.

She typed it on a Thursday night and posted it before she could reconsider.

“I went looking for the shortcut they took. The bought reviewer. The rigged vote. The drug that got waved through because somebody paid. I found the opposite every time. I even found the drug they pulled when the money could not save it. I kept waiting for the part where it fell apart, and instead I found people doing the work. I don’t know what to do with that except say it out loud.”

Sam the Skeptic saw it first. He wrote 4 words.

“That is the work.”

No celebration. No I told you so. Just acknowledgment, the only kind that counts. Debby read those 4 words 3 times. She had not gone searching for people saying things to validate her thoughts. She went with an open mind, with questions, and found answers using her toolkit that passed the test.

Auntie Nani had been reading the Lab quietly since Issue 008. Most people here had met her by now. She was the nurse and trial coordinator from the oncology office, the one who had been there for Maria’s labs and had sat with Vera before her first dose. Online, she almost never posted. This time she did. She started with what people get wrong about her job.

“People outside the building talk about this work as if it were only money. A stock price. A quarterly number. I stopped arguing with them a long time ago. I just wish they could see the part I see. A person signs a form that helps strangers they will never meet. And a room full of people who are paid to be careful decide to be careful anyway, because the name on the chart is somebody’s whole life.”

Then she told the group 2 things she had never said out loud to anyone outside the work.

“I have stayed at a site until 2 a.m. checking a single data point before it went up the chain. People think the drama is in the room where they decide to stop a trial. It is not. That board can only ever be as certain as the records underneath them. The certainty gets built at a desk, one verified line at a time, by people whose names never make the paper. I was one of those people.”

“And I coordinated a patient’s visits who did not make it to approval day. She would have qualified. She had been waiting. People ask how I keep doing this. I think of the physician who would stop at my desk at the end of a long night, look at a chart, and say, she is going to be fine. Not a promise, but rather as a hope said out loud, by someone who was not paid to hope. That is the part they never see. I have seen both faces of it.”

Then: “This is what it costs to get there.”

Nobody responded for 3 minutes. Vera wrote first. “Thank you for saying that.”

Debby the Skeptic broke the quiet. She had been sitting on a question for weeks, afraid to ask it in a group where she had said other things before.

“When people say the COVID vaccine was rushed, do they mean this kind of rush? Because I have been running the same questions on it, and I am not sure I know what I thought I knew.”

She did not wait for anyone to rescue her from it. She worked it the way she had just worked Gleevec. The fee did not move. The independent review did not move. The threshold for the evidence did not move. So what actually moved?

Rooty: The order. Some steps ran at the same time instead of one after another. And the financial risk of making doses before the trials finished got moved onto the government instead of the company. The clock moved. The bar did not.

Debby: So it was the same answer. I just had to run it myself.

Sam: Now you can run it on anything. And that does not even have to end with health claims or things about clinical research. Those questions work just about everywhere.

Here is the part that kept Debby up after she closed the laptop.

The record she had spent 3 weeks auditing was not made of committees. It was made of people. Vera was in a trial right now. Vera’s aunt had said yes to a trial 12 years ago for a drug that became a standard treatment, and she did not live long enough to take it. She said yes anyway, because someone had to be first.

When Debby went looking for the shortcut, the thing she actually found was a list of people who refused to take one. Some of them were reviewers and statisticians. Some of them were patients who would never meet the person their yes was for.

That is the work. That is who the work is.

She did one more thing before she slept. She found the message from the cousin who had told her, a year ago, that the FDA was bought. She did not argue. She sent him Rooty’s post about the drug that got pulled, and one line. I went looking for the shortcut. I could not find it. Thought you would want to see why.

Rooty had been posting quietly the whole time.

May 10, 2001. Priority review. 72 days from submission to approval.

41 years from the discovery of the chromosome to the approved drug.

Gleevec launched at $2,200 a month.

The Lab went quiet.

Debby: $2,200.

Sam did not explain it yet. That number was Issue 011. But everyone in the Lab could feel it sitting there, after 41 years and 72 days and a record built by people who would not cut the corner. The science arc was done. The access arc was starting.

The drug is approved. The price is set. Vera is in her trial.

Next issue: who actually got access to Gleevec. Who was in the room when the price was decided. What 85% of eligible patients have in common.

The views expressed on Root to Rx are my own and do not represent the views or positions of my employer, or any affiliated organization.

Root to Rx | 228 Park Ave S, #29976, New York, New York 10003, United States